Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Atrial FibrillationGerontology
Interventions
OTHER

questionnaires

scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)

Trial Locations (5)

42000

CHU de SAINT-ETIENNE, Saint-Etienne

42110

CH de FEURS, Feurs

42300

CH de ROANNE, Roanne

42400

CH de SAINT-CHAMOND, Saint-Chamond

42700

CH de FIRMINY, Firminy

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT02858518 - Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used? | Biotech Hunter | Biotech Hunter